Effect of Mesalamine and Prednisolone on TNBS Experimental Colitis, following Various Doses of Orally Administered Iron

Background. Experimental data suggest that oral iron (I.) supplementation can worsen colitis in animals. Aim. To investigate the influence of various concentrations of orally administered I. in normal gut mucosa and mucosa of animals with TNBS colitis, as well as the influence of Mesalamine (M.) and Prednisolone (P.) on the severity of TNBS colitis following orally administered I. Methods and Materials. 156 Wistar rats were allocated into 10 groups. Colitis was induced by TNBS. On the 8th day, all animals were euthanatized. Activity of colitis and extent of tissue damage were assessed histologically. The levels of tissue tumor necrosis factor-α (t-TNF-α) and tissue malondialdehyde (t-MDA) were estimated in all animal groups. Results. Moderate and high I. supplementation induced inflammation in the healthy colon and increased the activity of the experimentally induced TNBS colitis. Administration of M. on TNBS colitis following moderate iron supplementation (0.3 g/Kg diet) resulted in a significant improvement in the overall histological score as well as in two individual histological parameters. M. administration, however, did not significantly reduce the t-TNF-α levels (17.67 ± 4.92 versus 14.58 ± 5.71, P = 0.102), although it significantly reduced the t-MDA levels (5.79 ± 1.55 versus 3.67 ± 1.39, P = 0.000). Administration of M. on TNBS colitis following high iron supplementation (3.0 g/Kg diet) did not improve the overall histological score and the individual histological parameters, neither reduced the levels of t-TNF-α (16.57  ± 5.61 versus 14.65 ± 3.88, P = 0.296). However, M. significantly reduced the t-MDA levels (5.99 ± 1.37 versus 4.04 ± 1.41, P = 0.000). Administration of P. on TNBS colitis after moderate iron supplementation resulted in a significant improvement in the overall histological score as well as in three individual histological parameters. P. also resulted in a significant reduction in the t-TNF-α levels (17.67 ± 4.92 versus 12.64 ± 3.97, P = 0.003) and the t-MDA levels (5.79 ± 1.54 versus 3.47 ± 1.21, P = 0.001). Administration of P on TNBS colitis after high I. supplementation resulted in a significant improvement of the overall histological score and three individual histological parameters and significantly reduced the levels of t-TNF-α (16.6 ± 5.6 versus 11.85 ± 1.3, P = 0.001). Conclusion. I. can induce colonic inflammation and aggravate TNBS colitis. M. and P. can significantly improve the inflammatory process in the colonic mucosa in TNBS colitis aggravated by orally administered I. P. has a stable anti-TNF-α effect. These findings suggest that the harmful.

[1]  M. Kolber,et al.  Iron replacement therapy in inflammatory bowel disease patients with iron deficiency anemia: a systematic review and meta-analysis. , 2012, Journal of Crohn's & colitis.

[2]  P. Mahzouni,et al.  Preventive Therapy of Experimental Colitis with Selected iron Chelators and Anti-oxidants , 2012, International journal of preventive medicine.

[3]  W. Marsden.  I and J , 2012 .

[4]  I. Martínez,et al.  Depletion of luminal iron alters the gut microbiota and prevents Crohn's disease-like ileitis , 2010, Gut.

[5]  G. Corazza,et al.  Prevalence and pathogenesis of anemia in inflammatory bowel disease. Influence of anti-tumor necrosis factor-α treatment , 2010, Haematologica.

[6]  J. Mate,et al.  Oral and intravenous iron treatment in inflammatory bowel disease: Hematological response and quality of life improvement , 2009, Inflammatory bowel diseases.

[7]  P. Kosmidis,et al.  Colorectal cancer and inflammatory bowel disease: epidemiology, risk factors, mechanisms of carcinogenesis and prevention strategies. , 2009, Anticancer research.

[8]  M. Vatn,et al.  The association between water supply and inflammatory bowel disease based on a 1990-1993 cohort study in southeastern Norway. , 2008, American journal of epidemiology.

[9]  D. Rampton,et al.  Efficacy and tolerability of oral iron therapy in inflammatory bowel disease: a prospective, comparative trial , 2005, Alimentary pharmacology & therapeutics.

[10]  M. Karagianni,et al.  Favorable response to subcutaneous administration of infliximab in rats with experimental colitis. , 2005, World journal of gastroenterology.

[11]  T. Hausken,et al.  Effects of ferrous sulphate and non‐ionic iron–polymaltose complex on markers of oxidative tissue damage in patients with inflammatory bowel disease , 2005, Alimentary pharmacology & therapeutics.

[12]  T. Hausken,et al.  Low‐Dose Oral Ferrous Fumarate Aggravated Intestinal Inflammation in Rats With Dss‐Induced Colitis , 2005, Inflammatory bowel diseases.

[13]  V. Medici,et al.  Effects of iron manipulation on trace elements level in a model of colitis in rats. , 2005, World journal of gastroenterology.

[14]  T. Hausken,et al.  Oral ferrous fumarate or intravenous iron sucrose for patients with inflammatory bowel disease , 2005, Scandinavian journal of gastroenterology.

[15]  G. Mullin,et al.  Increased oxidative stress and decreased antioxidant defenses in mucosa of inflammatory bowel disease , 1996, Digestive Diseases and Sciences.

[16]  V. Medici,et al.  Effects of iron deprivation or chelation on DNA damage in experimental colitis , 2004, International Journal of Colorectal Disease.

[17]  R. Reifen,et al.  Iron Supplementation May Aggravate Inflammatory Status of Colitis in a Rat Model , 2000, Digestive Diseases and Sciences.

[18]  R. Reifen,et al.  5-ASA and lycopene decrease the oxidative stress and inflammation induced by iron in rats with colitis , 2004, Journal of Gastroenterology.

[19]  Jie Liao,et al.  Oxidative stress and ulcerative colitis-associated carcinogenesis: studies in humans and animal models. , 2003, Carcinogenesis.

[20]  T. Hausken,et al.  Ferrous Fumarate Deteriorated Plasma Antioxidant Status in Patients with Crohn Disease , 2003, Scandinavian journal of gastroenterology.

[21]  J. Allard,et al.  Iron supplementation increases disease activity and vitamin E ameliorates the effect in rats with dextran sulfate sodium-induced colitis. , 2002, The Journal of nutrition.

[22]  J. Allard,et al.  Effect of oral iron supplementation on oxidative stress and colonic inflammation in rats with induced colitis , 2001, Alimentary pharmacology & therapeutics.

[23]  J. Leza,et al.  N-(3-(aminomethyl)benzyl)acetamidine, an inducible nitric oxide synthase inhibitor, decreases colonic inflammation induced by trinitrobenzene sulphonic acid in rats. , 2001, Life sciences.

[24]  A. Öst,et al.  A reproducible grading scale for histological assessment of inflammation in ulcerative colitis , 2000, Gut.

[25]  Oldenburg,et al.  Iron supplementation affects the production of pro‐inflammatory cytokines in IL‐10 deficient mice , 2000, European journal of clinical investigation.

[26]  B. Ames,et al.  Both iron deficiency and daily iron supplements increase lipid peroxidation in rats. , 2000, The Journal of nutrition.

[27]  J. Ablin,et al.  Deferiprone, an oral iron chelator, ameliorates experimental colitis and gastric ulceration in rats , 1999 .

[28]  M. Neurath,et al.  Anti-interleukin 12 treatment regulates apoptosis of Th1 T cells in experimental colitis in mice. , 1999, Gastroenterology.

[29]  S. Fairweather-Tait,et al.  Oral ferrous sulfate supplements increase the free radical-generating capacity of feces from healthy volunteers. , 1999, The American journal of clinical nutrition.

[30]  J. Ablin,et al.  Deferiprone, an oral iron chelator, ameliorates experimental colitis and gastric ulceration in rats. , 1999, Inflammatory bowel diseases.

[31]  A. Bylund-Fellenius,et al.  Experimental colitis induced by dextran sulphate sodium in mice: beneficial effects of sulphasalazine and olsalazine , 1998, Alimentary pharmacology & therapeutics.

[32]  J. Fischer,et al.  Iron supplementation does not affect cell proliferation or aberrant crypt foci development in the colon of sprague-dawley rats. , 1998, The Journal of nutrition.

[33]  N. Rifai,et al.  Vitamins A and E serum levels in children and young adults with inflammatory bowel disease: effect of disease activity. , 1998, Journal of pediatric gastroenterology and nutrition.

[34]  G. Kollias,et al.  Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice , 1997, European journal of immunology.

[35]  G. Brittenham,et al.  Role of iron in NF-kappa B activation and cytokine gene expression by rat hepatic macrophages. , 1997, The American journal of physiology.

[36]  W. Doe,et al.  Depleted mucosal antioxidant defences in inflammatory bowel disease. , 1995, Free radical biology & medicine.

[37]  T. Macdonald,et al.  Tumor necrosis factor α-producing cells in the intestinal mucosa of children with inflammatory bowel disease , 1994 .